In NSCLC, KRAS mutations are present in approximately 30% of lung adenocarcinomas and 5% of squamous cell carcinomas; these alterations are more common in western (26%) than in Asian (11%) populations and in smokers (30%) than non-smokers (10%) [11,12,13]. The gene discussed is KRAS; the disease is lung adenocarcinoma.